CANADIAN NATIONAL STOCK EXCHANGE · DRUG
-1.45% · -$1.14 · Vol 165.9K
Market closed · last close 4:00 PM ET · price as of 16:01:21 ET
Bright Minds Biosciences Inc

Bright Minds Biosciences Inc

Biotechnology
$77.42
Card
Relationship Map

Veridion Score

BETALOW CONF · 4/6 factorsMethodology
Earnings absence reason unknown · Analyst data unavailable at compute time
DRUG
Bright Minds Biosciences Inc
Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
SELL BIAS

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

32/ 100
Veridion Score
SELL BIAS · LOW confidence
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 4/6 factors with data · Fri Aug 21 · last completed session · Markets closed · resumes Mon 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is DRUG moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading DRUG catalysts
About Bright Minds Biosciences Inc
Biotechnology
Listed since
2021
Employees
25
Country
US

Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$78.89
Day high
$79.56
Day low
$77.23
Previous close
$78.56
52W high
$95.98
-19.34% from high
52W low
$38.80
68% of range
Market cap
$759.6M
EPS
$-3.3996
Beta
1.51
Shares out
9.8M
Volume
165.9K
0.82× rel vol
Avg volume
203.3K
VWAP
$78.27
Price history computed in-house
1W
+1.28%
1M
+8.54%
3M
-7.28%
1Y
+76.11%
YTD
-0.79%
SMA 50 $72.32 · above
SMA 200 $77.08 · above
52W position 68%

DRUG overview

Veridion Score
32
Registered · 2026-08-21
4 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around DRUG.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading DRUG Form 4 filings
Public disclosures

Congress activity in DRUG

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified Congressional disclosure is present for DRUG in the cached public ledger.

Federal contracts

DRUG contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for DRUG in this window.
Lobbying spend

DRUG lobbying filings, year to date.

Registered lobbying filings matched to Bright Minds Biosciences Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for DRUG in this window.
Loading news for DRUG
Analyst ratings
Sovereign unlock shows live analyst consensus for DRUG.
Options
Sovereign unlock shows live options positioning for DRUG.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.